Stem cell therapies for treating osteoarthritis: prescient or premature?
Authors: Whitworth Deanne J, Banks Tania A
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary: Stem Cell Therapies for Osteoarthritis in Equines Mesenchymal stem cell (MSC) therapy has generated considerable commercial interest for treating osteoarthritis in horses, yet Whitworth and Banks' 2014 review reveals a troubling gap between marketing claims and robust scientific evidence. The authors examined in vitro and in vivo research across three stem cell types—embryonic, induced pluripotent, and mesenchymal stem cells—comparing published efficacy data with the therapeutic promises made to practitioners and horse owners. Their critical finding was stark: whilst preliminary human clinical trials show encouraging results, the veterinary treatments currently available rely on minimal controlled evidence, suggesting that commercialisation has substantially outpaced rigorous validation. The review highlights that most equine applications focus on MSCs for joint disease, yet many supporting studies lack adequate controls and long-term follow-up data necessary to establish genuine clinical benefit over placebo or conventional interventions. Practising farriers, vets, and physiotherapists should approach stem cell marketing claims with healthy scepticism until larger, well-designed trials provide concrete evidence of efficacy—particularly important given the significant costs involved and the potential for delayed or foregone conventional treatment in valuable animals.
Read the full abstract on PubMed
Practical Takeaways
- •Stem cell therapies for osteoarthritis in horses and dogs are currently available commercially but lack sufficient rigorous clinical evidence to support their use
- •The gap between marketing claims and scientific proof suggests practitioners should approach these treatments with caution until better-controlled studies demonstrate efficacy
- •Tissue engineering approaches show more promise than current stem cell therapies and may represent the future direction of this treatment modality
Key Findings
- •Mesenchymal stem cells have been deployed therapeutically in clinical settings for osteoarthritis in horses and dogs
- •A marked disparity exists between purported benefits of stem cell therapies and their proven abilities in rigorously controlled scientific studies
- •Current animal stem cell therapies are supported by very limited clinical evidence despite preliminary human trial data being encouraging
- •Tissue engineering is proposed as the future direction for stem cell-based therapy for osteoarthritis rather than current commercial approaches